Literature DB >> 24141889

¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.

H Kjölhede1, G Ahlgren, H Almquist, F Liedberg, K Lyttkens, T Ohlsson, O Bratt.   

Abstract

PURPOSE: To compare (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) with extended pelvic lymph node dissection (ePLND) for the detection of lymph node metastases in a large cohort of patients with high-risk prostate cancer.
MATERIALS AND METHODS: Patients with prostate-specific antigen levels between 20 and 99 ng/mL and/or Gleason score 8-10 cancers, planned for treatment with curative intent following a negative or inconclusive standard bone scan, were investigated with (18)F-fluorocholine PET/CT followed by an ePLND. None of the patients received hormonal therapy prior to these staging procedures. Results for PET/CT were compared on a per-patient basis with histopathology from ePLND. Sensitivity, specificity, positive and negative predictive values were calculated.
RESULTS: PET/CT detected a total of 76 suspected lymph node metastases and four suspected bone metastases in 33 (29 %) of the 112 included patients. Of these, 35 suspected lymph node metastases, only within the anatomical template area of an ePLND, were found in 21 of the patients. Histopathology of the ePLND specimens detected 117 lymph node metastases in 48 (43 %) of the 112 patients. Per-patient sensitivity, specificity, positive and negative predictive values for (18)F-fluorocholine PET/CT for lymph node metastases within the ePLND template were 0.33, 0.92, 0.76 and 0.65, respectively. Only 11 patients had lymph nodes larger than 10 mm that would have been reported by CT alone.
CONCLUSIONS: (18)F-fluorocholine PET/CT detects lymph node metastases in a significant proportion of patients with high-risk prostate cancer with a high specificity, but low sensitivity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24141889     DOI: 10.1007/s00345-013-1189-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  23 in total

Review 1.  Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature.

Authors:  Gianluca Giannarini; Giuseppe Petralia; Harriet C Thoeny
Journal:  Eur Urol       Date:  2011-09-28       Impact factor: 20.096

2.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.

Authors:  Mohsen Beheshti; Larisa Imamovic; Gabriele Broinger; Reza Vali; Peter Waldenberger; Franz Stoiber; Michael Nader; Bernhard Gruy; Guenter Janetschek; Werner Langsteger
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

3.  18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer.

Authors:  Orazio Schillaci; Ferdinando Calabria; Mario Tavolozza; Carmelo Cicciò; Marco Carlani; Cristiana R Caracciolo; Roberta Danieli; Antonio Orlacchio; Giovanni Simonetti
Journal:  Nucl Med Commun       Date:  2010-01       Impact factor: 1.690

4.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

5.  Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

Authors:  Igle J de Jong; Jan Pruim; Philip H Elsinga; Willem Vaalburg; Han J Mensink
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

6.  High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy.

Authors:  Hanneke J M Meijer; Emile N van Lin; Oscar A Debats; J Alfred Witjes; Paul N Span; Johannes H A M Kaanders; Jelle O Barentsz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-02       Impact factor: 7.038

Review 7.  Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU).

Authors:  Pasquale Martino; Vincenzo Scattoni; Andrea B Galosi; Paolo Consonni; Carlo Trombetta; Silvano Palazzo; Carmen Maccagnano; Giovanni Liguori; Massimo Valentino; Michele Battaglia; Libero Barozzi
Journal:  World J Urol       Date:  2011-05-08       Impact factor: 4.226

8.  Radioisotope guided pelvic lymph node dissection for prostate cancer.

Authors:  F Wawroschek; H Vogt; D Weckermann; T Wagner; M Hamm; R Harzmann
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

9.  Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.

Authors:  Axel Häcker; Stefan Jeschke; Karl Leeb; Kurt Prammer; Josef Ziegerhofer; Wolfgang Sega; Werner Langsteger; Guenter Janetschek
Journal:  J Urol       Date:  2006-11       Impact factor: 7.450

10.  [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study.

Authors:  Mads H Poulsen; Kirsten Bouchelouche; Oke Gerke; Henrik Petersen; Birgitte Svolgaard; Niels Marcussen; Niels Svolgaard; Mattias Ogren; Werner Vach; Poul F Høilund-Carlsen; Ulla Geertsen; Steen Walter
Journal:  BJU Int       Date:  2010-09       Impact factor: 5.588

View more
  12 in total

Review 1.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

Review 2.  Imaging and evaluation of patients with high-risk prostate cancer.

Authors:  Marc A Bjurlin; Andrew B Rosenkrantz; Luis S Beltran; Roy A Raad; Samir S Taneja
Journal:  Nat Rev Urol       Date:  2015-10-20       Impact factor: 14.432

3.  (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.

Authors:  Henrik Kjölhede; Göran Ahlgren; Helen Almquist; Fredrik Liedberg; Kerstin Lyttkens; Thomas Ohlsson; Ola Bratt
Journal:  World J Urol       Date:  2015-04-01       Impact factor: 4.226

4.  [Positron-emission tomography in urooncology].

Authors:  T Maurer; H Kübler; J E Gschwend; M Eiber
Journal:  Urologe A       Date:  2015-07       Impact factor: 0.639

Review 5.  Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer.

Authors:  Andrei Fodor; Andrea Lancia; Francesco Ceci; Maria Picchio; Morten Hoyer; Barbara Alicja Jereczek-Fossa; Piet Ost; Paolo Castellucci; Elena Incerti; Nadia Di Muzio; Gianluca Ingrosso
Journal:  World J Urol       Date:  2018-05-11       Impact factor: 4.226

Review 6.  PET imaging for lymph node dissection in prostate cancer.

Authors:  Elena Incerti; Paola Mapelli; Luigi Gianolli; Maria Picchio
Journal:  World J Urol       Date:  2016-10-17       Impact factor: 4.226

Review 7.  PSMA PET and Radionuclide Therapy in Prostate Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

8.  Diagnostic accuracy of F18 flucholine PET/CT for preoperative lymph node staging in newly diagnosed prostate cancer patients; a systematic review and meta-analysis.

Authors:  Seong-Jang Kim; Sang Woo Lee
Journal:  Br J Radiol       Date:  2019-07-05       Impact factor: 3.039

9.  Sensitivity and specificity of PET/CT regarding the detection of lymph node metastases in prostate cancer recurrence.

Authors:  Daniar K Osmonov; Diana Heimann; Isa Janßen; Alexey Aksenov; Almut Kalz; Klaus Peter Juenemann
Journal:  Springerplus       Date:  2014-07-04

10.  Diagnostic Challenges in Prostate Cancer and 68Ga-PSMA PET Imaging: A Game Changer?

Authors:  Maseeh uz Zaman; Nosheen Fatima; Areeba Zaman; Mahwsih Sajid; Unaiza Zaman; Sidra Zaman
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.